Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Ausun Pharmaceutical Co Scaled Net Operating Assets Chart
SHSE:603229 vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Zhejiang Ausun Pharmaceutical Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Ausun Pharmaceutical Co Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhejiang Ausun Pharmaceutical Co's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Zhejiang Ausun Pharmaceutical Co's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.55 mean?
Zhejiang Ausun Pharmaceutical Co (SHSE:603229) has a Scaled Net Operating Assets of 0.55 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Zhejiang Ausun Pharmaceutical Co and its competitors.
Is Zhejiang Ausun Pharmaceutical Co's Scaled Net Operating Assets too high?
Zhejiang Ausun Pharmaceutical Co's current Scaled Net Operating Assets is 0.55. Overall, Zhejiang Ausun Pharmaceutical Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Ausun Pharmaceutical Co's Scaled Net Operating Assets compare to VRTX and REGN?
Zhejiang Ausun Pharmaceutical Co's Scaled Net Operating Assets of 0.55 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Zhejiang Ausun Pharmaceutical Co and its competitors. Zhejiang Ausun Pharmaceutical Co's current Scaled Net Operating Assets is 0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Ausun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co (SHSE:603229) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥10.26, compared to a current price of ¥8.10 — trading 21.1% below its estimated fair value. The current Scaled Net Operating Assets is 0.55. Zhejiang Ausun Pharmaceutical Co's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Zhejiang Ausun Pharmaceutical Co (SHSE:603229), the current Scaled Net Operating Assets is 0.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥8.10 is trading 21.1% below its estimated GF Value™ of ¥10.26.
GuruFocus considers Zhejiang Ausun Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603229:
Scaled Net Operating Assets: 0.55
GF Value™: ¥10.26 vs. price of ¥8.10 (21.1% below fair value)
No single metric tells the full story. See the SHSE:603229 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Ausun Pharmaceutical Co Business Description
Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.
82GF Score
Get the complete analysis for SHSE:603229
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603229 has been successfully added to your 
